Pharmaceuticals FDA Approves Expanded Use of Almirall’s Crisiri to Treat Actinic Keratosis Last updated: June 12, 2024 2:26 am By bexib 0 Min Read Share SHARE Klisyri is currently available in a 350 mg package size as a topical treatment for actinic keratosis of the face or scalp. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article How to Dropship on eBay (2024 Guide) Next Article Decision time has come for Ontario farmers struggling with unseeded land – RealAgriculture Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Rachel Bruford named Chief Commercial Officer of Splendid Hospitality Group Hospitality & Tourism What does aggregate mean in insurance? A simple guide Insurance Pyrex pays restitution for Made in USA fraud. You may be eligible for a refund! Manufacturing What is plaguing the Anglosphere? – Econ Rib Economy